LIQUID PLASMA: A SOLUTION TO OPTIMIZING EARLY AND BALANCED PLASMA RESUSCITATION IN MASSIVE TRANSFUSION.

BACKGROUND Early and balanced resuscitation for traumatic hemorrhagic shock is associated with decreased mortality, making timely plasma administration imperative. However, fresh frozen plasma (FFP) thaw time can delay administration, and the shelf life of thawed FFP limits supply and may incur wastage. Liquid plasma (LP) offers an attractive alternative given immediate transfusion potential and extended shelf life. As such, we hypothesized that the use of LP in the massive transfusion protocol (MTP) would improve optimal plasma:red blood cell (RBC) ratios, initial plasma transfusion times, and clinical outcomes in the severely injured patient. METHODS Using Trauma Quality Improvement Program data from our level one trauma center we evaluated MTP activations from 2016-2018. Type A LP use was instated April 2017. Prior to this, thawed FFP was solely used. Plasma:RBC ratios and initial plasma transfusion times were compared in MTP patients before and after LP implementation. Patient and injury characteristics were accounted for using linear regression analysis. Secondary outcomes of mortality, 28-day recovery and complications were evaluated using Cox proportional hazards regression. RESULTS A total of 95 patients were included (pre-LP=39; post-LP=56). Time to initial plasma transfusion and plasma:RBC ratios at 4- and 24-hours were improved post-LP implementation with a coinciding reduction in RBC units transfused (p<0.05). In a 28-day Cox proportional hazards regression LP implementation was associated with favorable recovery (HR 3.16; 95% confidence interval [CI], 1.60-6.24, p<0.001) and reduction in acute kidney injury (HR 0.092; 95% CI, 0.011-0.77, p=0.027). No post-LP patients with blood group type B or AB (n=9) demonstrated evidence of hemolysis within 24-hours of type A LP transfusion. CONCLUSION Initial resuscitation with LP optimizes early plasma administration and improves adherence to transfusion ratio guidelines. Furthermore, LP offers a solution to inherent delays with FFP and is associated with improved clinical outcomes, particularly 28-day recovery and odds of acute kidney injury. LP should be considered as an alternative to FFP in MTPs. LEVEL OF EVIDENCE Therapeutic/Care Management, level IV.